世界の脊髄性筋萎縮症（SMA）治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Spinal Muscular Atrophy (SMA) Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4894
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、87ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、脊髄性筋萎縮症（SMA）治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口薬、注射薬）、用途別市場規模（乳児、子供、大人）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・脊髄性筋萎縮症（SMA）治療薬の市場動向
・企業の競争状況、市場シェア
・脊髄性筋萎縮症（SMA）治療薬の種類別市場規模と予測2016-2027（経口薬、注射薬）
・脊髄性筋萎縮症（SMA）治療薬の用途別市場規模と予測2016-2027（乳児、子供、大人）
・脊髄性筋萎縮症（SMA）治療薬の北米市場規模2016-2027（アメリカ、カナダ）
・脊髄性筋萎縮症（SMA）治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・脊髄性筋萎縮症（SMA）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・脊髄性筋萎縮症（SMA）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・脊髄性筋萎縮症（SMA）治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Biogen、Novartis、Genentech）
・結論

Spinal Muscular Atrophy (SMA), also known as spinal muscular atrophy, is a type of disease in which the degeneration of motor neurons in the anterior horn of the spinal cord leads to muscle weakness and muscular atrophy.The Spinal muscular atrophy drugs Can effectively alleviate the symptoms of the disease.

Market Analysis and Insights: Global Spinal Muscular Atrophy (SMA) Drugs Market
The global Spinal Muscular Atrophy (SMA) Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Spinal Muscular Atrophy (SMA) Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Spinal Muscular Atrophy (SMA) Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Spinal Muscular Atrophy (SMA) Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Spinal Muscular Atrophy (SMA) Drugs market.

Global Spinal Muscular Atrophy (SMA) Drugs Scope and Market Size
Spinal Muscular Atrophy (SMA) Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Spinal Muscular Atrophy (SMA) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by End User in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Oral Medicine
Injection Medicine

Segment by End User
Baby
Child
Adult

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Biogen
Novartis
Genentech

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral Medicine
1.2.3 Injection Medicine
1.3 Market by Application
1.3.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Share by End User: 2016 VS 2021 VS 2027
1.3.2 Baby
1.3.3 Child
1.3.4 Adult
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Perspective (2016-2027)
2.2 Spinal Muscular Atrophy (SMA) Drugs Growth Trends by Regions
2.2.1 Spinal Muscular Atrophy (SMA) Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Spinal Muscular Atrophy (SMA) Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Spinal Muscular Atrophy (SMA) Drugs Industry Dynamic
2.3.1 Spinal Muscular Atrophy (SMA) Drugs Market Trends
2.3.2 Spinal Muscular Atrophy (SMA) Drugs Market Drivers
2.3.3 Spinal Muscular Atrophy (SMA) Drugs Market Challenges
2.3.4 Spinal Muscular Atrophy (SMA) Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Revenue
3.1.1 Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Revenue (2016-2021)
3.1.2 Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Spinal Muscular Atrophy (SMA) Drugs Revenue
3.4 Global Spinal Muscular Atrophy (SMA) Drugs Market Concentration Ratio
3.4.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy (SMA) Drugs Revenue in 2020
3.5 Spinal Muscular Atrophy (SMA) Drugs Key Players Head office and Area Served
3.6 Key Players Spinal Muscular Atrophy (SMA) Drugs Product Solution and Service
3.7 Date of Enter into Spinal Muscular Atrophy (SMA) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Spinal Muscular Atrophy (SMA) Drugs Breakdown Data by Type
4.1 Global Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by Type (2016-2021)
4.2 Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Type (2022-2027)

5 Spinal Muscular Atrophy (SMA) Drugs Breakdown Data by End User
5.1 Global Spinal Muscular Atrophy (SMA) Drugs Historic Market Size by End User (2016-2021)
5.2 Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by End User (2022-2027)

6 North America
6.1 North America Spinal Muscular Atrophy (SMA) Drugs Market Size (2016-2027)
6.2 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type
6.2.1 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021)
6.2.2 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2022-2027)
6.2.3 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2027)
6.3 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User
6.3.1 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2021)
6.3.2 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2022-2027)
6.3.3 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2027)
6.4 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country
6.4.1 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2016-2021)
6.4.2 North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size (2016-2027)
7.2 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Type
7.2.1 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021)
7.2.2 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2022-2027)
7.2.3 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2027)
7.3 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by End User
7.3.1 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2021)
7.3.2 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2022-2027)
7.3.3 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2027)
7.4 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country
7.4.1 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2016-2021)
7.4.2 Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size (2016-2027)
8.2 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Type
8.2.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by End User
8.3.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2021)
8.3.2 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2022-2027)
8.3.3 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2027)
8.4 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region
8.4.1 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size (2016-2027)
9.2 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type
9.2.1 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2027)
9.3 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User
9.3.1 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2021)
9.3.2 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2022-2027)
9.3.3 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2027)
9.4 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country
9.4.1 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size (2016-2027)
10.2 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Type
10.2.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by End User
10.3.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2021)
10.3.2 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2022-2027)
10.3.3 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2027)
10.4 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country
10.4.1 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Spinal Muscular Atrophy (SMA) Drugs Introduction
11.1.4 Biogen Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2016-2021)
11.1.5 Biogen Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Spinal Muscular Atrophy (SMA) Drugs Introduction
11.2.4 Novartis Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Genentech
11.3.1 Genentech Company Details
11.3.2 Genentech Business Overview
11.3.3 Genentech Spinal Muscular Atrophy (SMA) Drugs Introduction
11.3.4 Genentech Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2016-2021)
11.3.5 Genentech Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oral Medicine
Table 3. Key Players of Injection Medicine
Table 4. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Growth by End User (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Regions (2016-2021)
Table 8. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Regions (2022-2027)
Table 10. Spinal Muscular Atrophy (SMA) Drugs Market Trends
Table 11. Spinal Muscular Atrophy (SMA) Drugs Market Drivers
Table 12. Spinal Muscular Atrophy (SMA) Drugs Market Challenges
Table 13. Spinal Muscular Atrophy (SMA) Drugs Market Restraints
Table 14. Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Players (2016-2021)
Table 16. Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Spinal Muscular Atrophy (SMA) Drugs as of 2020)
Table 17. Ranking of Global Top Spinal Muscular Atrophy (SMA) Drugs Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Spinal Muscular Atrophy (SMA) Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Spinal Muscular Atrophy (SMA) Drugs Product Solution and Service
Table 21. Date of Enter into Spinal Muscular Atrophy (SMA) Drugs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type (2016-2021)
Table 25. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Spinal Muscular Atrophy (SMA) Drugs Market Size Share by End User (2016-2021) & (US$ Million)
Table 28. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by End User (2016-2021)
Table 29. Global Spinal Muscular Atrophy (SMA) Drugs Forecasted Market Size by End User (2022-2027) (US$ Million)
Table 30. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by End User (2022-2027) & (US$ Million)
Table 31. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2021) (US$ Million)
Table 34. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2022-2027) & (US$ Million)
Table 35. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2021) (US$ Million)
Table 40. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2022-2027) & (US$ Million)
Table 41. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2021) (US$ Million)
Table 46. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2021) (US$ Million)
Table 52. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2022-2027) & (US$ Million)
Table 53. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2016-2021) (US$ Million)
Table 58. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by End User (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 61. Biogen Company Details
Table 62. Biogen Business Overview
Table 63. Biogen Spinal Muscular Atrophy (SMA) Drugs Product
Table 64. Biogen Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2016-2021) & (US$ Million)
Table 65. Biogen Recent Development
Table 66. Novartis Company Details
Table 67. Novartis Business Overview
Table 68. Novartis Spinal Muscular Atrophy (SMA) Drugs Product
Table 69. Novartis Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2016-2021) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. Genentech Company Details
Table 72. Genentech Business Overview
Table 73. Genentech Spinal Muscular Atrophy (SMA) Drugs Product
Table 74. Genentech Revenue in Spinal Muscular Atrophy (SMA) Drugs Business (2016-2021) & (US$ Million)
Table 75. Genentech Recent Development
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Type: 2020 VS 2027
Figure 2. Oral Medicine Features
Figure 3. Injection Medicine Features
Figure 4. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by End User: 2020 VS 2027
Figure 5. Baby Case Studies
Figure 6. Child Case Studies
Figure 7. Adult Case Studies
Figure 8. Spinal Muscular Atrophy (SMA) Drugs Report Years Considered
Figure 9. Global Spinal Muscular Atrophy (SMA) Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Spinal Muscular Atrophy (SMA) Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Regions: 2020 VS 2027
Figure 12. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Regions (2022-2027)
Figure 13. Global Spinal Muscular Atrophy (SMA) Drugs Market Share by Players in 2020
Figure 14. Global Top Spinal Muscular Atrophy (SMA) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Spinal Muscular Atrophy (SMA) Drugs as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Spinal Muscular Atrophy (SMA) Drugs Revenue in 2020
Figure 16. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type (2016-2021)
Figure 17. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share by Type (2022-2027)
Figure 18. North America Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Spinal Muscular Atrophy (SMA) Drugs Market Share by Type (2016-2027)
Figure 20. North America Spinal Muscular Atrophy (SMA) Drugs Market Share by End User (2016-2027)
Figure 21. North America Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2016-2027)
Figure 22. United States Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Spinal Muscular Atrophy (SMA) Drugs Market Share by Type (2016-2027)
Figure 26. Europe Spinal Muscular Atrophy (SMA) Drugs Market Share by End User (2016-2027)
Figure 27. Europe Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2016-2027)
Figure 28. Germany Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Share by End User (2016-2027)
Figure 37. Asia-Pacific Spinal Muscular Atrophy (SMA) Drugs Market Share by Region (2016-2027)
Figure 38. China Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Share by Type (2016-2027)
Figure 46. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Share by End User (2016-2027)
Figure 47. Latin America Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2016-2027)
Figure 48. Mexico Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Share by End User (2016-2027)
Figure 53. Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Market Share by Country (2016-2027)
Figure 54. Turkey Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Spinal Muscular Atrophy (SMA) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Biogen Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2016-2021)
Figure 58. Novartis Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2016-2021)
Figure 59. Genentech Revenue Growth Rate in Spinal Muscular Atrophy (SMA) Drugs Business (2016-2021)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size, Status and Forecast 2021-2027
QFJ1-5351 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、脊髄性筋萎縮症（SMA）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ヌシネルセン、オナセムノゲンアベパルボベック）、用途別市場規模（タイプ1SMA、タイプ2 SMA、その他）、主要地域別市場規...

世界の脊髄性筋萎縮症遺伝子検出市場規模・現状・予測（2021年-2027年）

Global Spinal Muscular Atrophy Genetic Detection Market Size, Status and Forecast 2021-2027
QFJ1-4895 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、脊髄性筋萎縮症遺伝子検出の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（遺伝子スクリーニング、生殖遺伝子検査、診断検査、遺伝子保因者検査、発症前検査）、用途別市場規模（病院、クリニック、診断センター）...

世界の球脊髄性筋萎縮症治療市場規模・現状・予測（2021年-2027年）

Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, Status and Forecast 2021-2027
QFJ1-6018 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、球脊髄性筋萎縮症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（5α-レダクターゼ阻害剤、ゴナドトロピン放出ホルモンアゴニスト）、用途別市場規模（病院、整形外科クリニック、外来手術センター）、主要...

世界のデュシェンヌ型筋ジストロフィー(DMD)治療薬市場規模・現状・予測（2021年-2027年）

Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size, Status and Forecast 2021-2027
QFJ1-5718 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、デュシェンヌ型筋ジストロフィー(DMD)治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（エテプリルセン、デフラザコート、アタルレン）、用途別市場規模（病院、診療所、ホームケア）、主要地域別市場規...

世界のゴーシェ病（GD）治療薬市場規模・現状・予測（2021年-2027年）

Global Gaucher Disease (GD) Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5747 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、ゴーシェ病（GD）治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（酵素補充療法、基質減少療法）、用途別市場規模（非神経障害性ゴーシェ病、神経障害性ゴーシェ病）、主要地域別市場規模（北米、アメリカ...

世界の遅発性ジスキネジア(TD)治療薬市場規模・現状・予測（2021年-2027年）

Global Tardive Dyskinesia (TD) Treatment Drugs Market Size, Status and Forecast 2021-2027
QFJ1-6032 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、遅発性ジスキネジア(TD)治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（バルベナジン、デュテトラベナジン）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、ア...

世界の腎臓癌＆腎細胞癌（RCC）治療薬市場規模・現状・予測（2021年-2027年）

Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2021-2027
QFJ1-5819 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、腎臓癌＆腎細胞癌（RCC）治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アフィニトール（エベロリムス）、アバスチン（ベバシズマブ）、カボメティ（カボザンチニブ）、インリタ（アキシチニブ）、ネク...

世界の多系統萎縮症治療薬市場規模・現状・予測（2021年-2027年）

Global Multiple System Atrophy Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-4535 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、多系統萎縮症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（アンレ-138b、AZD-3241、CS-10BR05、NPT-20011、PBT-434、PD-01）、用途別市場規模（病院、クリニ...

世界のmRNAワクチン＆治療薬市場規模・現状・予測（2021年-2027年）

Global mRNA Vaccine And Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-4530 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、mRNAワクチン＆治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（感染症、がん、その他）、用途別市場規模（病院、研究所）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、イン...

世界の黒色腫診断＆治療薬市場規模・現状・予測（2021年-2027年）

Global Melanoma Diagnostics and Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-4487 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、黒色腫診断＆治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（結節型黒色腫、表在性黒色腫、無色素性黒色腫、その他）、用途別市場規模（病院、診断センター、医療機関、その他）、主要地域別市場規模（北米...

世界の脊髄性筋萎縮症（SMA）治療市場規模・現状・予測（2021年-2027年） Spinal muscular atrophy treatment market growth is driven by a significant increase in the number of product launches despite the relative rarity of the disorder and high costs associated with the approved drugs. The treatment of spinal muscular atrophy through the gene therapy drug called Zolgensma…
世界の脊髄性筋萎縮症遺伝子検出市場規模・現状・予測（2021年-2027年） A detection method for Spinal Muscular Atrophy Market Analysis and Insights: Global Spinal Muscular Atrophy Genetic Detection Market The global Spinal Muscular Atrophy Genetic Detection market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 202…
世界の球脊髄性筋萎縮症治療市場規模・現状・予測（2021年-2027年） SBMA, mainly manifested as systemic muscle atrophy, paralysis and systemic muscle bundle tremor, patients with systemic muscle weakness, especially the weakness of the two lower limbs to walk, tongue muscle atrophy is usually one of the main symptoms. Market Analysis and Insights: Global Spinal and …
世界のデュシェンヌ型筋ジストロフィー(DMD)治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Drugs for Duchenne Muscular Dystrophy (DMD) Market The global Drugs for Duchenne Muscular Dystrophy (DMD) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in …
世界の多系統萎縮症治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Multiple System Atrophy Therapeutics Market The global Multiple System Atrophy Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and h…